



Security Simplified

Regd. Office: Marvel Edge, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune 411014.

Tel: +91 20 66813232 | Email: info@quickheal.com

CIN - L72200MH1995PLC091408

Ref No.: QHTL/Sec/SE/2020-21/56 February 03, 2021

The Manager, Corporate Services, BSE Limited, 14th floor, P J Towers, Dalal Street, Mumbai – 400 001

Ref: Security ID : QUICKHEAL

Security Code: 539678

The Manager,
Corporate Services,
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Symbol: QUICKHEAL

Carlos EO

Series : EQ

Subject: Outcome of Board Meeting held on February 03, 2021 for the quarter and nine months ended December 31, 2020

Dear Sir / Madam,

We wish to inform you that the Board of Directors at its meeting held on February 03, 2021 at the registered office/ through video conferencing which commenced at 02:45 PM and concluded at 05:50 PM, has approved following:

- 1. Unaudited Consolidated and Standalone Financial Results of the Company for the quarter and nine months ended December 31, 2020.
- 2. A copy of the Press Release being issued in respect of aforesaid financial results.
- 3. A Presentation in respect of aforesaid financial results
- 4. Pursuant to Regulation 33 of SEBI Regulations, we have enclosed herewith Limited Review Report for the un-audited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2020, from our Statutory Auditors, M/s MSKA & Associates, Chartered Accountants.

As permitted, this letter is being submitted under Sd/- mode due to work from home as per the Government advisory on Covid-19 and as a part of safety measure.

This is for your information and records.

For Quick Heal Technologies Limited

Sd/-

A. Srinivasa Rao Company Secretary

QUICK HEAL TECHNOLOGIES LIMITED

Regd. Office: Marvel Edge, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014 CIN: L72200MH1995PLC091408

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS OF QUICK HEAL TECHNOLOGIES LIMITED FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2020

Sr.		Quarter and al			(₹ in million, ex	(₹ in million, except earning per share	
No		December 31, 2020	Quarter ended			ths ended	Year ended
110		(Unaudited)	September 30, 2020	December 31, 2019	December 31, 2020	December 31, 2019	March 31, 2020
1	Income	(Chaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
	Revenue from operations						
	Other income	698,75	844.13	657.07	2,277.50	2,218.84	2001.0
	Total income	62.87	58,25	75,70	184.27	2,218.84	2,861.3
		761.62	902,38	732.77	2,461.77	2,452.38	315.90
2	Expenses		7		2,704177	2,932,38	3,177.3
_	Cost of raw materials consumed						
	Purchase of security software products	1,80	3.82	_	6.67	7.07	
	Changes in inventories of security software products	6.62	29.64	17,50	42.86	7.97	8.1
	Employee benefits expense	12.98	(2.97)	(1.03)	26.85	50.25	95.9
	Darwinia and	289.82	280.99	246.96		13.13	(3.8
	Depreciation and amortisation expense	49.57	48.79	53.91	832.34	768.38	1,014.1
	Other expenses	222,90	141.79	161.39	144.87	160.84	216.7
	Total expenses	583.69	502.06		491.93	541.04	833.0
		500.07	302.00	478.73	1,545.52	1,541.61	2,164.2
3	Profit / (loss) before exceptional items and tax (1-2)	177.93	400.22				
	200 200 700	177.55	400.32	254.04	916.25	910.77	1,013.11
4	Exceptional items						,
			√ 5		2	- 2	
5	Profit / (loss) before tax (3-4)						2 2
		177.93	400,32	254.04	916.25	910.77	1,013.1
	Tax expense					710.77	1,013.1
	Current tax			1			
	Pertaining to profit for the current period			1			
	Deferred tax	23,25	107,21	56.69	229.37	200 (1	
	Total tax expense	20.07	4.76	19.50	14.34	208,61	211.44
	тосят тах ехрепзе	43.32	111.97	76.19	243.71	37.98	57,56
7	Profit (Good) for the said (G.O.			70.15	243./1	246.59	269.00
•	Profit / (loss) for the period (5-6)	134.61	288.35	177.85	(50.51		
,	One was			177.03	672.54	664.18	744.11
3	Other comprehensive income, net of tax						
	Other comprehensive income not to be reclassified to profit or loss in subsequent periods:						
	Re-measurement of defined benefit plans	(4.17)	0.20		0.000		
	Other community	(4.17)	0.30	3.92	(2.87)	8.48	9.73
	Other comprehensive income to be reclassified to profit or loss in subsequent periods:		1				
	Exchange differences on translation of foreign operations	(0.37)	(2.43)	1.26	(2.00)		
		, , ,	(2.12)	1.20	(2.88)	0.35	2.16
	Total other comprehensive income	(4.54)	(2.12)				
		(4.54)	(2.13)	5.18	(5.75)	8.83	11.89
)	Total comprehensive income (after tax) (7+8)	130.07					
		130.07	286.22	183.03	666.79	673.01	756.00
)	Paid-up equity share capital (face value of ₹10 each)	612.05					
	,	642.05	642.03	642.03	642.05	642.03	642.03
	Other equity (as per balance sheet of previous accounting year)						0.12103
	provided descenting year)		30.				5,798.65
	Earnings per share of ₹10 each:						2,170,03
	(not annualised for the quarter)						
	()						
	a) Basic	310					
	Earnings per share of ₹10 each: (not annualised for the quarter) a) Basic b) Diluted	2.10	4.49	2.77	10.48	10.06	11.34
	113	2.09	4.49	2.77	10.47	10,05	11.34



	Audited standalone finan	cial information			0043 5000	
Sr. Particulars	Quarter ended			Nine Mon	ept earning per shar Year ended	
1 Revenue from operations	(Unaudited)	September 30, 2020 (Unaudited)	December 31, 2019 (Unaudited)	December 31, 2020 (Unaudited)	December 31, 2019 (Unaudited)	March 31, 2020 (Audited)
2 Profit before tax 3 Profit after tax	711.23 170.21 127.22	828.60 395.78 284.01	651,35 255.57 179,63	2,274.23 910.37 667.56	2,199,73 922.07 676,15	2,834.0 1,004.4 736.3

Notes to financial results:

- The above financial results for the quarter and period ended December 31, 2020 have been subjected to limited review by the statutory auditors of the Group and reviewed by the Audit Committee and approved by the Board of Directors of the Parent Company at the meeting held on February 3, 2021.
- During the year ended March 31, 2019, Parent Company had received notice of demand dated March 13, 2019, in relation to service tax under the provisions of Finance Act, 1994 for ₹ 387.43 million (excluding interest and penalties) covering the period from April 1, 2016 to June 30, 2017 on supply of anti-virus software in Company replied to the notice of demand to Commissioner of Goods and Service Tax, Pune.

During the earlier years, Parent Company received similar notice of demands in relation to service tax under the provisions of Finance Act, 1994 for ₹ 1,223.07 million (excluding penalty of ₹626.97 million and pre-deposit, if any) covering the period with the Customs, Excise and Service Tax Appellate Tribunal, New Delhi for the period March 1, 2014 to March 31, 2016 and Service Tax Appellate Tribunal, New Delhi for the period March 1, 2014 to March 31, 2016 and Service Tax Appellate Tribunal, New Delhi for the period March 1, 2014 to March 31, 2016 and Service Tax Appellate Tribunal, New Delhi for the period March 1, 2014 to March 31, 2016 and Service Tax Appellate Tribunal, New Delhi for the period March 1, 2014 to March 31, 2016 and Service Tax Appellate Tribunal, New Delhi for the period March 1, 2014 to March 31, 2016 and Service Tax Appellate Tribunal, New Delhi for the period March 31, 2016 and Service Tax Appellate Tribunal, New Delhi for the period March 31, 2016 and Service Tax Appellate Tribunal, New Delhi for the period March 31, 2016 and Service Tax Appellate Tribunal, New Delhi for the period March 31, 2016 and Service Tax Appellate Tribunal, New Delhi for the period March 31, 2016 and Service Tax Appellate Tribunal, New Delhi for the period March 31, 2016 and Service Tax Appellate Tribunal, New Delhi for the period March 31, 2016 and Service Tax Appellate Tribunal Service Tax Appellate Tr

The Hon'ble Customs, Excise & Service Tax Appellate Tribunal (CESTAT), Principal Bench, New Delhi, vide its judgment (Order No. 50022/2020) dated January 09, 2020 (Service Tax Appeal No. 51175 of 2016), has set aside the Service Tax 2014.

Based on this latest judgement of CESTAT, New Delhi, technical circular issued by Government authorities and an independent legal opinion obtained by the Parent Company in earlier years, the Parent Company is confident to get relief and set aside for balance period from April 01, 2014 to June 30, 2017. Accordingly, no provision/contingent liability had been recognized/disclosed in the financial statements.

The Commissioner of Service Tax, Delhi has preferred an appeal against the above said Order passed by the Hon'ble Customs, Excise & Service Tax Appellate Tribunal (CESTAT) amounting to ₹560.71 million and hearing for condonation of delay of

The Group is engaged in providing security software solutions. The Chief Operating Decision Maker (CODM) reviews the information pertaining to revenue of each of the target customer group (segments) viz. retail, enterprise & government and separate reportable operating segment as defined by Ind AS 108 "Operating segments".

4 Estimated uncertainty relating to COVID-I9 outbreak

The Management has made an assessment of the impact of COVID-19 on the Group's operations, financial performance and position as at and for the quarter ended December 31, 2020 and has concluded that the impact is primarily on the operational existing and future customer orders, cash flow forecasts, commitments with suppliers, etc. The Group has performed sensitivity analysis on the assumptions used and based on current indicators of future economic conditions, the Group expects to Accordingly, no further adjustments have been made to the financial results.

Considering the dynamic nature of the issue, the impact of the global health pandemic may be different from that estimated as at the date of approval of these financial results and the Group will continue to closely monitor any material changes to future

- The Indian Parliament has approved the Code on Social Security 2020 which subsumes the Provident Fund and the Gratuity Act and rules thereunder. The Ministry of Labour and Employment has also released draft rules thereunder on November 13, 2020 and has invited suggestions from stakeholders which are under active consideration by the Ministry. The Group will evaluate the rules, assess the impact if any, and account for the same once the rules are notified and becomes effective.
- 6 Previous period's figures have been regrouped / reclassified wherever necessary to make them comparable with the current period's classification / disclosure,

For and on behalf of the Board of Directors

Place: Pune

Date: February 03, 2021

Kailash Katkar
Managing Director
& Chief Executive Officer

Regd. Office: Marvel Edge, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014 CIN: L72200MH1995PLC091408

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS OF QUICK HEAL TECHNOLOGIES LIMITED FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2020

	L -	Quarter ended			(₹ in million, except earning Nine Months ended Year ended		
Sr. No	Particulars	December 31, 2020	September 30, 2020	December 31, 2019	December 31, 2020	December 31, 2019	March 31, 2020
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income						
	Revenue from operations	698,75	844.13	(57.05			
	Other income	62.87		657.07	2,277.50	2,218.84	2,861.3
	Total income	761.62	58,25 902,38	75.70 732.77	184,27 2,461.77	233.54	315.9
2	Expenses			102.11	2,401.77	2,452.38	3,177.3
2	Cost of raw materials consumed						
	Purchase of security software products	1.80	3.82		6.67	7.97	8.:
	Changes in inventories of a wait and	6.62	29.64	17.50	42.86	50,25	95.9
	Changes in inventories of security software products	12,98	(2.97)	(1.03)	26.85	13.13	
	Employee benefits expense	289.82	280.99	246.96	832,34	768,38	(3.8
	Depreciation and amortisation expense	49.57	48.79	53.91	144.87	160.84	1,014.1
	Other expenses	222.90	141.79	161.39	491.93		216.7
	Total expenses	583,69	502.06	478.73	1,545.52	541.04 1,541.61	833.0 2,164.2
3	Profit / (loss) before exceptional items and tax (1-2)	477 00			,	1,0 11.01	2,104.2
	(1-2)	177.93	400.32	254.04	916.25	910.77	1,013.1
4	Exceptional items		-	221			
5	Profit / (loss) before tax (3-4)						*
	(Jan)	177.93	400.32	254.04	916.25	910.77	1,013.1
6	Tax expense					1	
	Current tax		1				
	Pertaining to profit for the current period	23,25	107.21	55.50			
	Deferred tax	20,07		56.69	229.37	208,61	211.4
	Total tax expense	43.32	4.76	19.50 76.19	14.34	37.98	57.5
7	D-104 (0) 5. (1) 1.(7.0)		111.57	76.19	243.71	246.59	269.0
,	Profit / (loss) for the period (5-6)	134.61	288,35	177.85	672.54	664.18	744.1
8	Other comprehensive income, net of tax						
	Other comprehensive income not to be reclassified to profit or loss in						
	subsequent periods:						
	Re-measurement of defined benefit plans	(4,17)	0,30	3,92	(2.87)	2.42	
	Other comprehensive income to be reclassified to profit or loss in subsequent perio	* 111 *		3,72	(2.87)	8.48	9.7
	Exchange differences on translation of foreign operations	(0.37)	(2.43)	1,26	(2.00)		
		(-11.)	(2.43)	1,20	(2,88)	0.35	2.1
	Total other comprehensive income	(4.54)	(2.13)	5.18	(5.75)	8.83	11.89
9	Total comprehensive income (after tax) (7+8)	130.07	206.22				
		130.07	286.22	183.03	666.79	673.01	756.0
10	Paid-up equity share capital (face value of ₹10 each)	642.05	642,03	642.03	642.05	642.03	642.0
11	Other equity (as per balance sheet of previous accounting year)				3	1.4,00	042,0.
	cho	ologies	640.	*	1/2/		5,798.65
	Earnings per share of ₹10 each:	96					
	(not annualised for the quarter)	100				7.50	
	Earnings per share of ₹10 each: (not annualised for the quarter) a) Basic b) Diluted	2.10					
	b) Diluted	2.10	4.49	2.77	10.48	10.06	11.34



Regd. Office: Marvel Edge, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune 411014 CIN: L72200MH1995PLC091408

NOTES TO THE STATEMENT OF CONSOLIDATED FINANCIAL RESULTS OF QUICK HEAL TECHNOLOGIES LIMITED FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2020

Notes to financial results:

- 1 The above financial results for the quarter and period ended December 31, 2020 have been subjected to limited review by the statutory auditors of the Group and reviewed by the Audit Committee and approved by the Board of Directors of the Parent Company
- 2 During the year ended March 31, 2019, Parent Company had received notice of demand dated March 13, 2019, in relation to service tax under the provisions of Finance Act, 1994 for ₹ 387,43 million (excluding interest and penalties) covering the period from April 1, 2016 to June 30, 2017 on supply of anti-virus software in Compact Disk. Company replied to the notice of demand to Commissioner of Goods and Service Tax, Pune.

During the earlier years, Parent Company received similar notice of demands in relation to service tax under the provisions of Finance Act, 1994 for ₹1,223.07 million (excluding penalty of ₹626,97 million and pre-deposit, if any) covering the period from March 1, 2011 to March 31, 2016 on supply of anti-virus software in Compact Disk. Parent Company had filed an appeal with Customs, Excise and Service Tax Appellate Tribunal, New Delhi for the period March 1, 2011 to March 31, 2014 and with the Customs, Excise and Service Tax Appellate Tribunal, Mumbai for the period April 1, 2014 to March 31, 2016.

The Hon'ble Customs, Excise & Service Tax Appellate Tribunal (CESTAT), Principal Bench, New Delhi, vide its judgment (Order No. 50022/2020) dated January 09, 2020 (Service Tax Appeal No. 51175 of 2016), has set aside the Service Tax demand for ₹560,71 million along with interest and penalty which was earlier confirmed by Directorate General of Central Excise Intelligence (DGCEI), New Delhi vide its Order of 2016 covering period from for the period March 1, 2011 to March 31, 2014.

Based on this latest judgement of CESTAT, New Delhi, technical circular issued by Government authorities and an independent legal opinion obtained by the Parent Company in earlier years, the Parent Company is confident to get relief and set aside for balance period from April 01, 2014 to June 30, 2017. Accordingly, no provision/contingent liability had been recognized/disclosed in the financial statements,

The Commissioner of Service Tax, Delhi has preferred an appeal against the above said Order passed by the Hon'ble Customs, Excise & Service Tax Appellate Tribunal (CESTAT) amounting to ₹560.71 million and hearing for condonation of delay of appeal

- The Group is engaged in providing security software solutions. The Chief Operating Decision Maker (CODM) reviews the information pertaining to revenue of each of the target customer group (segments) viz. retail, enterprise & government and mobile. However, based on similarity of activities/products, risk and reward structure, organisation structure and internal reporting systems, the Group has structured its operations into one operating segment viz. anti-virus and as such there is no separate reportable
- 4 Estimated uncertainty relating to COVID-I9 outbreak

The Management has made an assessment of the impact of COVID-19 on the Group's operations, financial performance and position as at and for the quarter ended December 31, 2020 and has concluded that the impact is primarily on the operational aspects of the business. In assessing the recoverability of receivables including receivables, investments, and other assets, the Group has considered internal and external information up to the date of approval of these financial results including status of existing and future customer orders, cash flow forecasts, commitments with suppliers, etc. The Group has performed sensitivity analysis on the assumptions used and based on current indicators of future economic conditions, the Group expects to gradually recover the carrying amount of these assets, the Group has also considered the impact of subsequent events in its assessment and concluded that there is no significant impact which is required to be recognised in the financial results. Accordingly, no further adjustments have been

Considering the dynamic nature of the issue, the impact of the global health pandemic may be different from that estimated as at the date of approval of these financial results and the Group will continue to closely monitor any material changes to future

- 5 The Indian Parliament has approved the Code on Social Security 2020 which subsumes the Provident Fund and the Gratuity Act and rules thereunder. The Ministry of Labour and Employment has also released draft rules thereunder on November 13, 2020 and has invited suggestions from stakeholders which are under active consideration by the Ministry. The Group will evaluate the rules, assess the impact if any, and account for the same once the rules are notified and becomes effective,
- 6 Previous period's figures have been regrouped / reclassified wherever necessary to make them comparable with the current period's classification / disclosure.

For and on behalf of the Board of Directors

Place: Pune

Date: February 03, 2021

Quick,

Managing Director & Chief Executive Officer

Regd. Office: Marvel Edge, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014

CIN: L72200MH1995PLC091408

STATEMENT OF STANDALONE FINANCIAL RESULTS OF QUICK HEAL TECHNOLOGIES LIMITED FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2020

Sr.	Particulars		Quarter ended			Nine months ended		
No		December 31, 2020 (Unaudited)	September 30, 2020 (Unaudited)	December 31, 2019 (Unaudited)	December 31, 2020	December 31, 2019	Year ended March 31, 2020	
1	Income		(onducted)	(Chandited)	(Unaudited)	(Unaudited)	(Audited)	
	Revenue from operations	711_23	828,60	651,35	2 274 22			
	Other income	62,31	57.19	75.07	2,274,23 182.13	2,199.73	2,834.0	
	Total income	773,54	885,79	726.42	2,456.36	232,29	313.4	
	<u></u>			7,20142	2,430.30	2,432.02	3,147.4	
2	Expenses Cost of raw materials consumed							
		1.80	3.82		6,67	7.97	0.1	
	Purchase of security software products	6.43	27.02	17,49	40.05	50.24	8,1 95,9	
	Increase / (decrease) in inventories of security software products Employee benefits expense	12,98	(2,96)	(1.01)	26.86	5.16	(16.1	
	Depreciation and amortisation expense	285,97	277,11	243.01	820 62	757.86	999.9	
	Other expenses	49,56	48.74	53.90	144.80	160.76	216.6	
	Total expenses	246.59	136,28	157,46	506.99	527.96	815.4	
	Total expenses	603,33	490.01	470.85	1,545.99	1,509,95	2,119.8	
3	Profit / (Loss) before exceptional items and tax (1-2)	170.21	395.78				2,117.0	
4	Exceptional items (refer note 3)	170.21	333.76	255.57	910.37	922.07	1,027.5	
	St. American	170	X 🕏	*	\$	§ [23,1	
5	Profit / (Loss) before tax (3-4)	170.21	395,78	255.57	910,37			
6	Tax expense			233.37	310.37	922.07	1,004.4	
	Current tax							
	Pertaining to profit for the current period			1		-		
	Deferred tax	22,92	107.01	56.44	228,47	207,94	210.45	
	Total tax expense	20,07	4.76	19.50	14,34	37.98	57.50	
	7.5.10	42.99	111.77	75.94	242.81	245.92	268.0	
7	Profit / (Loss) for the period (5-6)	127.22	284.01	179,63	667.56	676,15	F2.6.04	
8	Other comprehensive income, net of tax				007.50	0/0.13	736.39	
	Other comprehensive income not to be reclassified to profit or loss in subsequent periods:	1 1						
	Re-measurement of defined benefit plans	(4.17)	0,30	2.00				
	Other comprehensive income to be a large to the second sec	(5,4,6)	0,30	3.92	(2,87)	8.48	9,73	
	Other comprehensive income to be reclassified to profit or loss in subsequent periods	-	:¥:	ē	-			
	Total other comprehensive income	(4.17)	0.30	2.00				
9	Total comprehensive income (after tax) (7+8)	0.000		3.92	(2.87)	8.48	9.73	
	and the second s	123.05	284.31	183.55	664.69	684.63	746.12	
10	Paid-up equity share capital (face value of ₹ 10 each)	642.05	642.03	642.03	(40.05			
11	Other equity (as per balance sheet of previous accounting year)	1	0-12,03	042,03	642.05	642,03	642,03	
							5,840.10	
12	0 1						51	
	(not annualised except for the year ended March)				1			
	a) Basic							
	b) Diluted	1.98	4.43	2.80	10.40	10.24	11.23	
_	***************************************	1.98	4.43	2.80	10.40	10.23	11.22	





Regd. Office: Marvel Edge, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014

CIN: L72200MH1995PLC091408 NOTES TO THE STATEMENT OF STANDALONE FINANCIAL RESULTS OF QUICK HEAL TECHNOLOGIES LIMITED FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2020

Notes to financial results:

The above financial results for the quarter and nine months ended December 31, 2020 have been subjected to limited review by the statutory auditors of the Company and reviewed by the Audit Committee and approved by the Board of Directors of the

During the year ended March 31, 2019, Company had received notice of demand dated March 13, 2019, in relation to service tax under the provisions of Finance Act, 1994 for ₹387,43 million (excluding interest and penalties) covering the period from April 1, 2016 to June 30, 2017 on supply of anti-virus software in Compact Disk. Company replied to the notice of demand to Commissioner of Goods and Service Tax, Pune.

During the earlier years, Company received similar notice of demands in relation to service tax under the provisions of Finance Act, 1994 for ₹ 1,223,07 million (excluding penalty of ₹ 626,97 million and pre-deposit, if any) covering the period from March 1, 2011 to March 31, 2016 on supply of anti-virus software in Compact Disk. Company had filed an appeal with Customs, Excise and Service Tax Appellate Tribunal, New Delhi for the period March 1, 2011 to March 31, 2014 and with the Customs, Excise and

The Hon'ble Customs, Excise & Service Tax Appellate Tribunal (CESTAT), Principal Bench, New Delhi, vide its judgment (Order No. 50022/2020) dated January 09, 2020 (Service Tax Appeal No. 51175 of 2016), has set aside the Service Tax demand for \$\epsilon\$. 560.71 million along with interest and penalty which was earlier confirmed by Directorate General of Central Excise Intelligence (DGCEI), New Delhi vide its Order of 2016 covering period from for the period March 1, 2011 to March 31, 2014.

Based on this latest judgement of CESTAT, New Delhi, technical circular issued by government authorities and an independent legal opinion obtained by the Company in earlier years, the Company is confident to get relief and set aside for balance period from April 01, 2014 to June 30, 2017. Accordingly, no provision/contingent liability had been recognized/disclosed in the financial statements.

The Commissioner of Service Tax, Delhi has preferred an appeal against the above said Order passed by the Hon'ble Customs, Excise & Service Tax Appellate Tribunal (CESTAT) amounting to ₹ 560.71 million and hearing for condonation of delay of appeal

3 Impairment of investments

Included in exceptional items

Particulars			Stane	dalone		(₹ in million
		Quarter ended		Nine mor	nths ended	Year ended
17/2	December 31, 2020	September 30, 2020	December 31, 2019	December 31, 2020	December 31, 2019	March 31, 2020
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Impairment of investment in wholly owned subsidiaries	•					23.17

- The Company is engaged in providing security software solutions. The Chief Operating Decision Maker (CODM) reviews the information pertaining to revenue of each of the target customer group (segments) viz. retail, enterprise & government and mobile. However, based on similarity of activities/products, risk and reward structure, organisation structure and internal reporting systems, the Company has structured its operations into one operating segment viz. anti-virus and as such there is no separate reportable
- The Indian Parliament has approved the Code on Social Security 2020 which subsumes the Provident Fund and the Gratuity Act and rules thereunder. The Ministry of Labour and Employment has also released draft rules thereunder on November 13, 2020 and has invited suggestions from stakeholders which are under active consideration by the Ministry. The Company will evaluate the rules, assess the impact if any, and account for the same once the rules are notified and becomes effective
- Estimated uncertainty relating to COVID-19 outbreak

The management has made an assessment of the impact of COVID-19 on the Company's operations, financial performance and position as at and for the quarter ended December 31, 2020 and has concluded that the impact is primarily on the operational aspects of the business. In assessing the recoverability of receivables including receivables, investments, and other assets, the Company has considered internal and external information up to the date of approval of these financial results including status of existing and future customer orders, cash flow forecasts, commitments with suppliers, etc. The Company has performed sensitivity analysis on the assumptions used and based on current indicators of future economic conditions, the Company expects to gradually recover the carrying amount of these assets, the Company has also considered the impact of subsequent events in its assessment and concluded that there is no significant impact which is required to be recognised in the financial results. Accordingly,

Considering the dynamic nature of the issue, the impact of the global health pandemic may be different from that estimated as at the date of approval of these financial results and the Company will continue to closely monitor any material changes to future

Previous period's figures have been regrouped / reclassified wherever necessary to make them comparable with the current period's classification / disclosure.

For and on behalf of the Board of Directors

Place: Pune

Date: February 03, 2021

Kailash Katkar Managing Director

& Chief Executive Officer



FOR IMMEDIATE RELEASE

Quick Heal Technologies Limited announces 9MFY21 Results

- Revenue at ₹2,278 mln up 2.6% Y-o-Y
- EBITDA at ₹877 mln up 5% Y-o-Y with EBITDA margin of 38.5%
- PAT at ₹673 mln up 1% Y-o-Y
- Continues to be a debt free company

Pune, February 3, 2021: Quick Heal Technologies Limited ("Quick Heal"), one of the leading providers of cybersecurity and data protection solutions to consumers, businesses and Government, reported its reviewed and unaudited results for the quarter and nine months ended 31th December 2020.

Consolidated Financial Highlights:

Particulars (₹ million)	Q3FY21	Q3FY20	Y-o-Y Change	9MFY21	9MFY20	Y-o-Y Change
Revenue	698.75	657.07	6.34%	2,277.50	2,218.84	2.64%
EBITDA	164.63	232.25	-29.12%	876.85	838.07	4.63%
EBITDA Margin	23.56%	35.35%	-1179bps	38.50%	37.77%	73bps
PAT	134.61	177.85	-24.31%	672.54	664.18	1.26%
PAT Margin	19.26%	27.07%	-780bps	29.53%	29.93%	-40bps

Dr. Kailash Katkar, Managing Director & Chief Executive Officer, Quick Heal Technologies Limited, said; "We delivered good revenue performance during the third quarter as the Indian economy slowly started recovering from the Covid-19 pandemic. On the R&D front, with the appointment of industry veterans like Sanjay Agrawal and Bibhuti Kar, we have accelerated new product development efforts to strengthen our enterprise business under 'Seqrite'. Furthermore, we recently announced additional investment in Israel based company – L7 Defense, reiterating our commitment to invest in disruptive technologies that will shape the future of cybersecurity while supporting innovative start-ups. With economy slowly recovering and increase in cybersecurity awareness, we are confident to end the year on a positive note."

Mr. Nitin Kulkarni, Chief Financial Officer, Quick Heal Technologies Limited, added; "We have performed better in what traditionally remains a weak quarter for us with quarterly revenue growing 6.3% YoY basis. With economy slowly recovering, we have increased our investments in advertisements and



continued focus in R&D innovations have affected our margins. Our balance sheet remains strong with zero debt and a cash and cash equivalents balance of ₹4,787 mln."

Segmental Performance for nine months ended 31st December 2020

- ✓ Retail segment revenue at ₹2,038 million compared to ₹1,876 in 9MFY20. Retail segment contributed 81.5% to total revenue in 9MFY21
- ✓ Enterprise and Government segment revenue at ₹464 million compared to ₹468 mln in 9MFY20. Enterprise segment contributed 18.5% to total revenue in 9MFY21

Key updates:

Quick Heal Technologies signed a definitive agreement to make an additional strategic investment
of USD 2 million in L7 Defense, an Israel based cybersecurity start-up. The investment enables
Quick Heal to expand its range of enterprise solutions under the 'Seqrite' umbrella and introduce
L7's flagship products in market stronghold of India as well as other regions in APAC and EMEA.

About Quick Heal Technologies Limited

Quick Heal Technologies Limited is one of the leading providers of IT Security and Data Protection Solutions with a strong footprint in India and an evolving global presence. Incorporated in the year 1995, with a registered office in Pune, it is a player in cybersecurity with presence in B2B, B2G and B2C segments and multiple product categories – endpoints, network, data and mobility.

It helps in simplifying security by delivering best-in-class protection against advanced cyber-threats to millions of its customers and enterprises. Quick Heal's portfolio includes solutions under the widely recognized brand names 'Quick Heal' and 'Seqrite' across various operating systems and devices.

For more information about the Company, please visit our website www.quickheal.co.in

Safe Harbor Statement

This document may contain forward-looking statements about Quick Heal Technologies Limited, which are based on the beliefs, opinions, and expectations of the company's management as the date of this press release and the companies do not assume any obligation to update their forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. These statements are not the guarantees of future performance and involve risks and uncertainties that are difficult to predict. Consequently, readers should not place any undue reliance on such forward-looking statements.

For further details please contact

Company



Quick Heal Technologies Limited

CIN No: L72200MH1995PLC091408

Mr. Akash Gosavi

Email Id: akash.gosavi@quickheal.co.in

Tel. No.: +91 20 6681 3287







This presentation and the accompanying slides (the "Presentation"), which have been prepared by Quick Heal Technologies Ltd. (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

This presentation contains certain forward-looking statements concerning the Company's future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward-looking statements become materially incorrect in future or update any forward-looking statements made from time to time by or on behalf of the Company.

Quick Heal acknowledges the ownership rights of third parties to the intellectual property rights mentioned in this document. Other logos/trademarks mentioned in the presentation belongs to respective owners and used only for reference purpose.







Agenda

01

02

03

04

05



Q3FY21 Earnings Highlights



Company Overview



Industry Overview



The Quick Heal Advantage





Q3 & 9M FY21 Earnings Highlights







Q3FY21 Revenue at

€699_{mln}

up 6.3%from ₹ 657 mln in O3FY20

9MFY21 Revenue at

₹2,278 mln

up 2.6% from ₹ 2,219 mln in 9MFY20 **EBITDA**



9MFY21 EBITDA at

₹**877** ml

up 4.6% from ₹ 838 mln in 9MFY20

EBITDA margin at

38.5%

in 9MFY21 up 73 bps from 37.7% in 9MFY20

PAT

9MFY21 PAT at

₹673 mln

up 1.3% from ₹ 664 mln in 9MFY20

PAT margin at

29.5%

In 9MFY21 marginally down 40 bps from 29.9% in 9MFY20

9MFY21 Revenue split





Enterprise + Government 18.5%


New enterprise customers with more than 500 users added in FY21:

222	>=500 to <=999	>=1,000 to <=4999	>=5000	Total
Q1	3	0	0	3
Q2	14	5	0	19
Q3	12	5	1	18



Company at a glance





Vision

To be the trusted global leader in securing the digital world

Mission


Secure our customers by providing innovative, most preferred and valued security solutions, services and knowledge

Protect information and interactions on all types of networks, devices & things globally

Build a healthy business and organization

Our journey





Over 25 years of simplifying security

Scripting a new success story In the cybersecurity industry

Quick Heal





₹ 2,038 mln 9MFY21 Revenue*















₹464 mln 9MFY21

SECRITE

Revenue*








*Based on net revenues before adjusting for sales incentives

- India's first listed cybersecurity products company
- A "Make in India" product configured to secure countries, cities and companies
- Quick Heal undisputed leader in the retail segment
- Segrite making inroads in the SMB & enterprise segment
- Quick Heal Security Labs a team of highly efficient security researchers, analysts engineers leverages combination of Al, cloud and patented technologies deliver timely and advanced protection
- Solutions to secure across platforms

Shareholder information



Shareholding structure – 31st December 2020



Shareholder Information (as on 31st December 2020)

NSE Ticker	QUICKHEAL
BSE Ticker	539678
Market Cap (INR mln)	11,085
% Free-float	27.17%
Free-float market cap (INR mln)	3,012
Total Debt (INR mln)	-
Cash & Cash Equivalents (INR mln)	4,787
Shares Outstanding	6,42,05,368
3M ADTV (Shares)*	5,69,929
3M ADTV (INR mln)*	95.6
Industry	IT Software Products

^{*}Source: NSE






INDUSTRY OVERVIEW


2020 Cyber threat landscape shows that...




Detection Highlights - 2020



Indian Industries most at risk



States most affected




12

Source: Segrite Threat Report 2021 Source: Segrite Threat Report 2021 Source: Quick Heal Threat Report 2021

...cyber-attacks continue to grow in scale and sophistication...







Source: Quick Heal Threat Report 2021

Cyber-attacks that grabbed headlines NEW

From Ransomware, hackers shifting focus to Ransomhack: Segrite - The Hindu Business Line (December 20,2020)

Big Basket confirms data breach of 2 crore users – India Today (November 09, 2020)

SolarWinds breach much worse than feared – CNBC (December 18, 2020)

Indian pharma firms at high ransomware attack risk in 2021: Seqrite - ET CIO (December 23, 2020)

Cyber crimes in India caused ₹ 1.25 lakh cr loss last year- The Hindu (October 21, 2020)

Increased cyber-attacks show why stringent cybersecurity laws are need of the hour - Business Today (January 10, 2021)

Source: IBM Source: Reputed News Outlets 13

...together with rapid growth in India's digital adoption...





Digital Transactions - INR Crore

Growth of Fast Payments


Fast Payment Systems - Volume (Lakh) and Value (₹ Crore) 2131730 2337541 140000 2500000 120000 2000000 100000 1500000 80000 125186 60000 1000000 40000 500000 20000 2011-12 2012-13 2013-14 2014-15 2015-16 2016-17 2017-18 2018-19 2019-20 - UPI Value (RHS)

Source: RBI Data

India in Numbers

Digital Payments in India

Digital Payments Volume (Crore) and Value (Lakh Crore)



Source: RBI Data



1.26b

People enrolled in the world's largest unique digital identity program



48.48%

Internet penetration in India in 2019



400m

Users engaged in social media



10.37GB

Average Wireless Data Usage per wireless data subscriber per month in 2019



19b


Application downloads in 2019




Rs.**6.9**8

Average cost to subscriber per GB wireless data

...is expected to increase Cybersecurity spending in India





15

Cybersecurity market in India is expected to grow at ~16% CAGR between 2019 to 2022 and become a \$3 bln market with security product market estimated to grow at ~17% to become \$1.6 bln market.

Source: PWC & DSCI report – Cyber Security India Market



Cyber threat predictions for 2021 and beyond





01

Threat Actors to switch from Ransomware to RansomHack: Double – Trouble for Enterprises 02

Targeted
Ransomware
attacks on
Healthcare and
Pharma Sector
to Surge

03

Techniques similar to Operation SideCopy 04

CobaltStrike:
Powerhouse of
Ethical Hackers
in the Hands of
Cyber Criminals

05

Increase in threats on Remote Work Infrastructure 06

Next wave of Crypto-miners

07

Coronavirus
themed threats to
divert from
precaution-based
to preventionbased

08

New additions in exploits leveraging weak crypto implementations

09

Deep-fakes to cyber-frauds

10

Automation in performing phishing attacks

11

Attacks on Red Team tools 12


Increase in attacks related to mobile banking

10



Quick Heal is well positioned to leverage its strengths to capture the future opportunities






Strong threat detection and prevention capabilities...









Powers **SIGNATURE-LESS** and **SIGNATURE-BASED** detections

Our best and the most innovative malware hunting engine brings together the best of the best!













...with State-of-the-Art

Research & Development leading to Innovations

25+ years of experience coupled with vast distribution network across India has helped us understand security market and issues faced by millions of users in depth which has led to consistent introduction of innovative products and solutions for our customers

Security Labs

Detect and analyze threat vectors across the globe and provide advanced protection to customers

Product Management Team

Ensures that we build the right products for the right markets at the right time



Incidence **Response Team**

H

Ensures customers are unaffected by critical attacks/ outages by responding promptly



Research & **Development**

Internet of Things (IOT) **Security Team**

Creating solutions to ensure all your connected devices are secure



Product Development Team


Designing & building cutting edge products & solutions



Quality **Assurance Team**




Trusted Partner to SECURE Enterprise Digital Transformation Journey



Product Portfolio - Home, SOHO & Mobile











Robust sales & distribution network in India





Robust pan India coverage

Complimentary support from Quick Heal

Zonal and regional sales team to engage and support channel

Landscape across Class B &C towns

Growing presence of T1 distributors across B&C towns. Strong network of T2 resellers - across Class B and Class

Metro Sales Coverage


Strong presence across the top metros in India. Coverage through T1 distributors and T2 resellers

Presence in Class A towns

Strong distribution across Class A towns backed by T2 resellers

QUICK HEAL Global Presence








Committed to deliver exceptional customer experience

- Multi-lingual end user support in English, Hindi and several other major regional Indian languages
 - Availability of data sheets, product videos and manuals on website for providing information on technical specifications, installation guide, upgrade mechanisms
 - Release of various articles, technical papers, quarterly threat reports and conducting webinars in the area of security software



Experienced Board of Directors





Dr. Kailash Katkar *MD & CEO*

Drives the strategic direction for the company while nurturing a strong leadership team to drive its execution



Dr. Sanjay Katkar Joint MD & CTO

Spearheads the creation and subsequent development of the core product technology



Mr. Shailesh Lakhani Non-Executive Director

Serves as the MD at Sequoia Capital India. Previously, he worked at Redknee's India subsidiary as the Managing Director



Mr. Amitabha Mukhopadhyay Independent Director

Over three decades of experience in corporate finance, legal and litigation, strategy and M&A. Served as the Group CFO of Thermax



Air Marshal (Retd) Bhushan Nilkanth Gokhale Independent Director

Served on the board of defense PSUs and adviser to government institutions. Appointed as Independent Security Advisor in Ministry of Home Affairs.



Mr. Mehul Savla Independent Director

Serves as Director for RippleWave Equity Advisors LLP. Previously worked at JP Morgan, ICICI Securities and SEBI



Ms. Apurva Joshi Independent Director

Certified bank forensic accounting professional and anti – money laundering expert

...along with strong Management...





Dr. Kailash Katkar *MD & CEO*

Co-founder of the Company

Has been the driving force in growing Quick Heal Technologies since it's inception.

A proven leader with a profound proficiency in developing strong client relationships, passion for building outstanding teams and a disciplined focus on operations & execution of strategy.



Dr. Sanjay Katkar Joint MD & CTO

Co-founder of the Company

Leads the global technology strategy & is responsible for the core research & development of the products.

Has served as the Director of Association of Anti-Virus Researchers, Asia and is a distinguished speaker at various industry forums.

Holds Master's degree in Computer Science from the University of Pune.

...and seasoned Leadership team





Mr. Nitin Kulkarni *CFO*

25+ years of experience in managing different aspects of finance in IT and Manufacturing Industry.

Previously held leadership positions at Tech Mahindra, KPIT, Atlas Copco India and Persistent Systems.

A member of the Institute of Chartered Accountants of India.



Ms. Reetu Raina

Responsible for driving HR and steering the company's people operations, culture and recruitment initiatives.

Ms. Raina holds extensive industry experience and has worked across sectors such as Telecom, BFSI, and IT.

She has held leadership roles with domain-leading brands such as TATA, HDFC Bank, and Amdocs. She was the Head of HR at Sterlite Technologies.



Mr. Sanjay Agrawal

Responsible for driving the overall product vision and strategy in line with market expectations.

Sanjay is an entrepreneurial engineering and product leader with two decades of experience and proven success in building cybersecurity products for the global markets.

A computer engineering graduate from University of Illinois, Sanjay holds a Ph.D. and M.S. from Stanford University in Electrical Engineering and Computer Science (EECS).

...and seasoned Leadership team



Mr. Bibhuti Kar Head of Research and Development

Responsible for driving company's development efforts leading a team of talented engineering professionals and security researchers.

Bibhuti brings with him over two and a half decades of rich experience in the global high-tech industry.

An alumnus of IIT Kharagpur with a master's in ECE, he has worked on missile communication systems with DRDO.



Mr. Kuldeep Raina Head, Global Enterprise Sales

Responsible for leading the enterprise and government sales strategy and managing the vertical on a global level.

Passionate technocrat with a rich flare for sales and ability to drive targets in dynamic business environment.

Over two decades of diverse sales experience including leadership roles in cybersecurity companies.





Mr. Deepak Mishra Head, Retail Sales

Responsible for enhancing market share and driving channel strategy for the retail brand.

Has extensive exposure in sales and distribution, channel management, and building a robust distribution to drive productivity and profitability.

Over two decades of experience in FMCG, Beverages, Telecom and IT Industries.

Strong brand recognition...



Best Enterprise IT Security Brand at the 11th NCN Innovative Product Award 2018



Best Protection rate In AV-Comparatives Test 2018



Certified as
'Approved
Corporate Endpoint
Protection' for
Windows by
'AV-Test' 2018



Best cybersecurity brand award at National Summit on Digital Innovation & Cybersecurity Summit 2018



Quick Heal Technologies

Recognized by NASSCOM's DSCI as 'Cybersecurity Product Pioneer

in India' 2019



Segrite

'Best Performance 2018' award for its Endpoint Security Solution from AV-Test Institute in Germany 2019



Quick Heal Technologies

Granted Patent for Anti-Ransomware Technology 2019 U.S. Patent No. US20160378988A1



Quick Heal Technologies

Granted Patent for its **Signatureless Behavior-based Detection Technology** 2019 U.S Patent No. US20170124327A1



Seqrite Endpoint Security

Certified as 'Top Product' for business users by 'AV-Test' in 2020



Quick Heal Total Security

Certified as **'Top Product'** for
consumers
by **'AV-Test'** in 2020

...backed by Certifications, Patents and...

International & ISO Certifications















Patented Technologies

USPTO 10,387,649

Signatureless Behaviour-based Detection Technology

USPTO 10,311,234

Anti-Ransomware technology

USPTO 8,973,136

System and method for protecting computer systems from malware attacks

USPTO 8,914,908

A completely automated computer implemented system and method for piracy control based on update requests

USPTO 8,347,389

System for protecting devices against virus attacks

USPTO 7,945,955

Virus detection in mobile devices having insufficient resources to execute virus detection software

Securing the future through our community initiatives





23,50,000+

Lives directly impacted since 2016



Cybersecurity

- Cybersecurity Awareness
- Cyber Shiksha for Suraksha
- Street Plays







45,000+

Lives directly impacted since 2016



Education

 Life Skills Education for underprivileged children





1,00,000+

Lives impacted since 2020



Covid-19 Relief Initiatives

- Free immunity boosters medicines to frontline workers
- Distribution of food grains to the needy
- Distribution of PPE kits to NGOs







Quick Heal Academy to drive the next generation of cyber security experts





Popular Courses

- ✓ Cyber Security and Forensics
- ✓ Cyber Threat Intelligence
- ✓ Malware Analysis & Reverse Engineering
- ✓ Security Operations Centre (SOC)
- ✓ Electronic Crime Scene Investigation

Offerings



CORPORATE TRAINING



NEED-BASED TRAINING



WORKSHOPS & SEMINARS



CONNECTING CYBER ECO-SYSTEM

Academy Partners

Savitribai Phule Pune University

Designed 'M-Tech in Information Security' Program for Savitribai Phule Pune University

Quantum University

W

Quantum

a

CHITKARA

MoU with Quantum University for a joint B.Tech (Hons.) with specialization in Cyber Security

Gujarat Forensic Sciences University

MoU with Gujarat Forensic Sciences University during Vibrant Gujarat 2017

Maharashtra Cosmopolitan Education Society

The society runs 30 institutes from its ultra modern campaigns located in Maharashtra

Chitkara University

MoU with Chitkara University Introduced an additional stream in Cyber Security for the four-year Undergraduate program


Deen Dayal Upadhyaya College


MoU with Deen Dayal Upadhyaya College, a constituent college of the University of Delhi



Q3FY21 - Consolidated Performance Highlights








9MFY21 - Consolidated Performance Highlights







Q3FY21 Segment performance






Retail


Enterprise & Government


Revenue break-up





Licenses Sold Analysis





9MFY21 Segment performance










Enterprise & Government


Revenue break-up





Licenses Sold Analysis





Q3FY21 - Profitability statement





DARTICUL ARS (F -		Standalone		Consolidated		
PARTICULARS (₹ mln)	Q3FY20	Q3FY21	% change	Q3FY20	Q3FY21	% change
Total Revenue	651.35	711.23	9.19%	657.07	698.75	6.34%
Direct Cost	20.87	26.18		20.87	26.39	
Gross Profit	630.48	685.05	8.66%	636.20	672.36	5.68%
Gross Margin	96.80%	96.32%	-48bps	96.82%	96.22%	-60bps
Operating Cost						
Research and Development (R&D)	125.80	159.06		125.81	159.06	
Sales and Marketing (S&M)	149.22	221.05		153.27	224.99	
General Administration (G&A)	121.06	147.48		124.87	123.68	
Total Expenditure	396.08	527.59	-33.20%	403.95	507.73	-25.69%
EBITDA	234.40	157.46	-32.82%	232.25	164.63	-29.12%
EBITDA Margin	35.99%	22.14%	-1385bps	35.35%	23.56%	-1179bps
Depreciation	53.90	49.56		53.91	49.57	
EBIT	180.50	107.90	-40.22%	178.34	115.06	-35.48%
EBIT Margin	27.71%	15.17%	-1254bps	27.14%	16.47%	-1068bps
Other Income	75.07	62.31		75.70	62.87	
Profit Before Tax	255.57	170.21	-33.40%	254.04	177.93	-29.96%
Tax	75.94	42.99		76.19	43.32	
Profit After Tax (PAT)	179.63	127.22	-29.18%	177.85	134.61	-24.31%
PAT Margin	27.58%	17.89%	-969bps	27.07%	19.26%	-780bps

9MFY21 - Profitability statement





DARTICIII ARS (# mln)	Standalone			Consolidated		
PARTICULARS (₹ mln)	9MFY20	9MFY21	% change	9MFY20	9MFY21	% change
Total Revenue	2,199.73	2,274.23	3.39%	2,218.84	2,277.50	2.64%
Direct Cost	81.97	88.67		89.99	91.53	
Gross Profit	2,117.76	2,185.56	3.20%	2,128.85	2,185.97	2.68%
Gross Margin	96.27%	96.10%	-17 bp s	95.94%	95.98%	4bps
Operating Cost						
Research and Development (R&D)	404.42	461.63		404.42	461.63	
Sales and Marketing (S&M)	480.02	482.74		492.59	494.71	
General Administration (G&A)	382.77	368.15		393.76	352.78	
Total Expenditure	1,267.22	1,312.52	-3.57%	1,290.78	1,309.12	-1.42%
EBITDA	850.54	873.04	2.65%	838.07	876.85	4.63%
EBITDA Margin	38.67%	38.39%	-28bps	37.77%	38.50%	73bps
Depreciation	160.76	144.80		160.84	144.87	
EBIT	689.78	728.24	5.58%	677.23	731.98	8.08%
EBIT Margin	31.36%	32.02%	66bps	30.52%	32.14%	162bps
Other Income	232.29	182.13		233.54	184.27	
Profit Before Tax	922.07	910.37	-1.27%	910.77	916.25	0.60%
Tax	245.92	242.81		246.59	243.71	
Profit After Tax (PAT)	676.15	667.56	-1.27%	664.18	672.54	1.26%
PAT Margin	30.74%	29.35%	-138bps	29.93%	29.53%	-40bps

Q3FY21 - Ratio analysis



I. 0/	Standalone		Consolidated	
In %	Q3FY20	Q3FY21	Q3FY20	Q3FY21
Expenses				
Direct Cost / Revenue	3.20%	3.68%	3.18%	3.78%
R&D / Revenue	19.31%	22.36%	19.15%	22.76%
S&M / Revenue	22.91%	31.08%	23.33%	32.20%
G&A / Revenue	18.59%	20.74%	19.00%	17.70%
Total Cost / Revenue	60.81%	74.18%	61.48%	72.66%
Margin				
Gross Margin	96.80%	96.32%	96.82%	96.22%
EBITDA	35.99%	22.14%	35.35%	23.56%
EBIT	27.71%	15.17%	27.14%	16.47%
PBT	39.24%	23.93%	38.66%	25.46%
PAT	27.58%	17.89%	27.07%	19.26%

9MFY21 - Ratio analysis



1 - 0/	Standalone		Consolidated	
In %	9MFY20	9MFY21	9MFY20	9MFY21
Expenses				
Direct Cost / Revenue	3.73%	3.90%	4.06%	4.02%
R&D / Revenue	18.38%	20.30%	18.23%	20.27%
S&M / Revenue	21.82%	21.23%	22.20%	21.72%
G&A / Revenue	17.40%	16.19%	17.75%	15.49%
Total Cost / Revenue	57.61%	57.71%	58.17%	57.48%
Margin				
Gross Margin	96.27%	96.10%	95.94%	95.98%
EBITDA	38.67%	38.39%	37.77%	38.50%
EBIT	31.36%	32.02%	30.52%	32.14%
PBT	41.92%	40.03%	41.05%	40.23%
PAT	30.74%	29.35%	29.93%	29.53%

Consolidated Balance Sheet





EQUITY AND LIABILITIES ([₹] mln)	Dec 31, 2019	Dec 31, 2020
Share Holder's Funds:		1
Equity Share Capital	642.03	642.05
Share application money pending allotment	-	-
Reserves and Surplus	6,025.54	6,472.75
Total Shareholder Funds	6,667.57	7,114.80
Non-Current Liabilities		
Net employee defined benefit liabilities	4.54	3.47
Other Non Current Liabilities	19.63	-
Total Non-Current Liabilities	24.17	3.47
Current Liabilities:		
Trade and Other Payables	343.08	493.01
Other Financial Liabilities	24.92	30.56
Other Current Liabilities	123.77	135.37
Net employee defined benefit liabilities	18.04	25.59
Current tax liabilities (Net)	13.43	14.18
Total Current Liabilities	523.24	698.71
Total Equity & Liabilities	7,214.98	7,816.98

ASSETS (₹ mln)	Dec 31, 2019	Dec 31, 2020
Non-Current Assets:		
Property, plant and equipment	1,522.74	1,408.76
Capital work-in-progress	38.23	34.00
Intangible assets	50.97	63.30
Non-current financial assets		
Investments in MF ,Tax-Free Bonds & others	348.32	174.04
Loan and Security Deposits	3.81	3.82
Bank Balances	3.92	3.40
Deferred tax assets (net)	45.87	12.49
Other non current assets	86.89	213.77
Total Non-Current Assets	2,100.75	1,913.58
Current assets:		
Inventories	45.60	32.88
Investment in Mutual Fund	2,675.92	3,945.08
Trade and other receivables	1,218.56	1,151.87
Bank Balances & Cash and Cash Equivalents	108.44	132.97
Investment in Fixed Deposit	923.00	576.63
Loan and security deposits	8.11	7.03
Interest accrued on FDR and Tax-Free Bonds	45.56	12.24
Other Current assets	89.04	44.70
Total Current Assets	5,114.23	5,903.40
Total Assets	7,214.98	7,816.98

Standalone Balance Sheet






EQUITY AND LIABILITIES (₹ mln)	Dec 31, 2019	Dec 31, 2020
Share Holder's Funds:	•	
Equity Share Capital	642.03	642.05
Share application money pending allotment	-	-
Reserves and Surplus	6,088.47	6,512.10
Total Shareholder Funds	6,730.50	7,154.15
Non-Current Liabilities		
Net employee defined benefit liabilities	4.54	3.47
Other Non Current Liabilities	19.63	-
Total Non-Current Liabilities	24.17	3.47
Current Liabilities:		
Trade and Other Payables	339.73	490.83
Other Financial Liabilities	24.92	30.56
Other Current Liabilities	122.83	133.77
Net employee defined benefit liabilities	18.04	25.59
Current tax liabilities (Net)	13.03	13.91
Total Current Liabilities	518.55	694.66
Total Equity & Liabilities	7,273.22	7,852.28

ASSETS (₹ mln)	Dec 31, 2019	Dec 31, 2020
Non-Current Assets:		
Property, plant and equipment	1,522.46	1,408.53
Capital work-in-progress	38.23	34.00
Intangible assets	50.78	63.12
Non-current financial assets		
Investments in MF, Tax-Free Bonds, Subsidiaries & others	465.51	296.32
Loan and Security Deposits	3.81	3.82
Bank Balances	3.92	3.40
Deferred tax assets (net)	45.87	12.49
Other non current assets	86.89	213.77
Total Non-Current Assets	2,217.47	2,035.45
Current assets:		
Inventories	41.04	32.66
Investment in Mutual Fund	2,675.92	3,945.08
Trade and other receivables	1,221.21	1,132.78
Bank Balances & Cash and Cash Equivalents	53.34	66.61
Investment in Fixed Deposit	923.00	576.63
Loan and security deposits	7.49	6.95
Interest accrued on FDR and Tax-Free Bonds	45.56	12.24
Other Current assets	88.19	43.88
Total Current Assets	5,055.75	5,816.83
Total Assets	7,273.22	7,852.28


Working capital analysis




At the end of December, 2019*



At the end of September, 2020**



At the end of December, 2020*



Note*

Receivable Days = [(Debtors/ Sales) X (275 days)] Inventory Days = [(Inventory/Sales) X (275 days)] Payable Days = [(Creditor/Sales) X (275 days)]

Note**

Receivable Days = [(Debtors/ Sales) X (183 days)] Inventory Days = [(Inventory/Sales) X (183 days)] Payable Days = [(Creditor/Sales) X (183 days)]


Calculation is based on net revenues before adjusting for sales incentives


Return ratio analysis



Return on Capital Employed*

Return on Equity*





- > Company is continuously evaluating strategic inorganic opportunities to invest across the cybersecurity ecosystem
- > Till such time the company invests its surplus cash in mutual funds, tax free-bonds and fixed deposits

RoCE = EBIT / Avg. Capital Employed (Equity + Debt)
Cash Adj. RoCE = EBIT / Avg. Cash Adj. Capital Employed (Equity + Debt - Cash & Cash Equivalents)

ROE = PAT / Avg. Equity





Thank You

Chief Financial Officer

Mr. Nitin Kulkarni
Nitin.Kulkarni@quickheal.co.in
+91-20-66813232

Company Secretary

Mr. Srinivas Anasingaraju cs@quickheal.co.in +91-20-66813232

CIN No: L72200MH1995PLC091408

www.quickheal.co.in

Annexure



Products Sold in following countries

- Italy
- Nigeria
- UAE
- Kenya
- Philippines
- Colombia
- Sri Lanka
- Singapore
- Congo
- Bangladesh
- Thailand
- Peru
- Australia

- Mexico
- Hong Kong
- Mauritius
- South Africa
- lordan
- Malaysia
- Gambia
- Venezuela
- USA
- Guinea
- New Zealand
- Cambodia
- Ecuador

- Chile
- South Korea
- Paraguay
- Saudi Arabia
- Turkey
- Aruba
- Ghana
- Tanzania
- Canada
- Panama
- Myanmar
- Honduras
- Rwanda

- Germany
- Malta
- Uganda
- El Salvador
- Croatia
- Nicaragua
- Zambia
- Poland
- Netherlands

- Sales & Support offices across India
 - Kolhapur

Chandigarh

New Delhi

Lucknow

Guwahati

Ahmedabad

laipur

• Patna

Indore

Surat

Nashik

Nagpur

Mumbai

Pune

- Raipur
- Kolkata
- Bhubaneshwar

Aurangabad

- Hyderabad
- Bangalore
- Chennai
- Kochi







Independent Auditor's Review Report on Consolidated Unaudited Quarterly and year to date financial results of the Group pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

The Board of Directors

Quick Heal Technologies Limited

- 1. We have reviewed the accompanying statement of consolidated unaudited financial results of Quick Heal Technologies Limited ('the Holding Company'), its subsidiaries, (the Holding Company and its subsidiaries together referred to as the 'Group') for the quarter ended December 31, 2020 and the year to-date results for the period from April 1, 2020 to December 31, 2020 ('the Statement'), being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ('the Regulation').
- 2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.





Chartered Accountants

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

Sr. No	Name of the Company	Relationship with the Holding Company
1	Quick Heal Technologies Japan K.K.	Wholly Owned Subsidiary
2	Quick Heal Technologies America Inc.	Wholly Owned Subsidiary
3	Quick Heal Technologies Africa Limited	Wholly Owned Subsidiary
4	Seqrite Technologies DMCC	Wholly Owned Subsidiary

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.





6. The consolidated unaudited financial results include the interim financial results of 4 subsidiaries which have not been reviewed by their auditors, whose interim financial results reflect total revenue of Rs. 12.93 million and Rs. 38.20 million, total net profit after tax of Rs. 7.19 million and Rs. 4.72 million and total comprehensive income of Rs. Rs. 7.19 million and Rs. 4.72 million for the quarter ended December 31, 2020 and for the period from April 1, 2020 to December 31, 2020, respectively, as considered in the consolidated unaudited financial results. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.

& Asso

For MSKA & Associates Chartered Accountants ICAI Firm Registration No.105047W

Nitin Manohar Jumani

Partner

Membership No.: 111700 UDIN: 21111700AAAAAS1423

Place: Pune

Date: February 03, 2021





Independent Auditor's Review Report on unaudited quarterly and year to date financial results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)

Regulations, 2015

The Board of Directors

Quick Heal Technologies Limited

- 1. We have reviewed the accompanying statement of unaudited standalone financial results of Quick Heal Technologies Limited ('the Company') for the quarter ended December 31, 2020 and the year to-date results for the period April 1, 2020 to December 31, 2020 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ('the Regulation').
- 2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether financial results are free of material misstatements. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.





4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited standalone financial results prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

Gred Accou

For MSKA & Associates
Chartered Accountants
ICAI Firm Registration No.105047W

Nitin Manohar Jumani

Partner

Membership No.: 111700 UDIN: 21111700AAAAAR7498

Place: Pune

Date: February 03, 2021